These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 10293290)
1. Rare diseases: new federal policies. Margolis RE Healthspan; 1989 May; 6(5):11-3. PubMed ID: 10293290 [No Abstract] [Full Text] [Related]
2. Orphan products development and some methods for maximizing the usefulness of research on rare diseases. Finkel MJ Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285 [No Abstract] [Full Text] [Related]
3. Clinical studies of safety and effectiveness of orphan products; availability of grants; request for applications. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Notice. Fed Regist; 1999 Jul; 64(141):40012-6. PubMed ID: 10558579 [TBL] [Abstract][Full Text] [Related]
4. Clinical studies of safety and effectiveness of orphan products; availability of grants; request for applications--FDA. Notice. Fed Regist; 1998 Aug; 63(150):41855-9. PubMed ID: 10181724 [TBL] [Abstract][Full Text] [Related]
5. Orphan Drug Act on congressional agenda. von Oehsen WH Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123 [TBL] [Abstract][Full Text] [Related]
6. Creation and development of the public service orphan drug Human Botulism Immune Globulin. Arnon SS Pediatrics; 2007 Apr; 119(4):785-9. PubMed ID: 17403850 [TBL] [Abstract][Full Text] [Related]
7. Orphan drug development for the treatment of rare chronic diseases. Moore ES Tex Hosp; 1988 Jul; 44(2):20-1. PubMed ID: 10288218 [No Abstract] [Full Text] [Related]
8. The Pharmaceutical Manufacturers Association Commission on Drugs for Rare Diseases. Goldstein GS Prog Clin Biol Res; 1985; 197():35-9. PubMed ID: 4070297 [No Abstract] [Full Text] [Related]
9. Developing treatments for inborn errors: incentives available to the clinician. Haffner ME Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976 [TBL] [Abstract][Full Text] [Related]
10. Lucrative niches: how drugs for rare diseases became lifeline for companies. Anand G Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531 [No Abstract] [Full Text] [Related]
12. Law and research could add up to profitable niche drugs. Haefner B Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162 [No Abstract] [Full Text] [Related]
14. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297 [TBL] [Abstract][Full Text] [Related]
15. Congress approves higher funding for all key AIDS programs. AIDS Policy Law; 1999 Dec; 14(22):6. PubMed ID: 11366660 [TBL] [Abstract][Full Text] [Related]
16. The browning of Canadian research. Korcok M Am Med News; 1979 Mar; 22(12):suppl 5-6. PubMed ID: 10308840 [No Abstract] [Full Text] [Related]
19. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899 [TBL] [Abstract][Full Text] [Related]
20. Rare diseases: identifying needs. Report of the National Commission on Orphan Diseases. Groft SC Am Pharm; 1990 Apr; NS30(4):33-40. PubMed ID: 2321528 [No Abstract] [Full Text] [Related] [Next] [New Search]